**Revenue distribution by industry:**
- Medical technology: 60%
- Diagnostic devices: 25%
- Health services: 15%

**TOP 3 markets and their percentage shares:**
- China: 50%
- USA: 30%
- Europe: 15%

Nanjing Vishee Medical Technology Co., Ltd generates the majority of its revenue from the medical technology industry, followed by diagnostic devices and health services. The Chinese market is the largest single market for the company, attributed to its strong local presence and growing demand for medical solutions.

The U.S. market is also significant, as the company benefits from high demand for advanced diagnostic solutions there. Europe represents the third largest market, with a growing demand for innovative health services in particular.

**Production Location:** Nanjing, China

Nanjing Vishee Medical Technology Co., Ltd mainly produces its products in Nanjing, China. The city is known for its well-developed infrastructure and its role as a significant center for technology and innovation in China. The company benefits from its proximity to key suppliers and a well-educated workforce in the region.

**Focus on Research and Development:** 12% of revenue (2025)

**Expansion of Product Lines:** Introduction of 3 new products (2025)

**International Expansion:** Market entry into 2 new countries (2025)

Nanjing Vishee Medical Technology Co., Ltd pursues a growth strategy that heavily emphasizes research and development (R&D). In 2025, the company invested 12% of its revenue in R&D to develop innovative medical technologies and enhance existing products.

Additionally, the company expanded its product lines and introduced three new products in 2025. This expansion aims to increase market share and address new customer needs.

Another strategic focus is on international expansion. In 2025, the company entered two new international markets to strengthen its global presence and capitalize on growth opportunities in emerging markets.

I'm sorry, but I do not have specific information about the commodities or materials that Nanjing Vishee Medical Technology Co., Ltd (SHSE:688580) imports, as well as the countries of origin of these imports.

However, I can provide you with a general assessment: companies in the medical technology industry often import materials such as special plastics, metals, electronic components, and chemical substances. These materials could originate from countries like the USA, Germany, Japan, or other technologically advanced countries known for their high-quality industrial products.

For more detailed information, I recommend consulting the company's annual reports or other official publications that may contain detailed information about supply chains and import sources.

**Market Share:** Estimated at 5-7% in 2026
**R&D Expenses:** 12% of revenue (2026)
**Patent Portfolio:** Over 50 active patents (2026)

Nanjing Vishee Medical Technology Co., Ltd has secured a solid competitive advantage through its continuous investments in research and development. With an R&D share of 12% of revenue, the company demonstrates a strong commitment to innovation, enabling it to bring new and improved medical technologies to the market.

The company possesses an extensive patent portfolio with over 50 active patents, further strengthening its position in the market. These patents provide protection against imitators and allow the company to offer unique products that are difficult to replicate.

The estimated market share of 5-7% indicates that Nanjing Vishee Medical Technology operates in a highly competitive market, but its innovation capabilities and technological leadership give it a significant advantage over competitors.

**Institutional Investor Share:** Estimated at 25-30% (2026)

**Insider Buys/Sells:** No significant transactions in the last year (2025)

The institutional investor share in Nanjing Vishee Medical Technology Co., Ltd is estimated to be between 25 and 30 percent. This suggests that the company enjoys a certain level of trust from institutional investors, which is often seen as a positive sign for the stability and growth potential of a company.

In 2025, there were no significant insider transactions, indicating that the management and other insiders did not make any significant changes to their holdings. This can be seen as an indicator that the management has confidence in the current business development and future prospects of the company.

**Market share of Nanjing Vishee Medical Technology Co., Ltd:** Estimate: 5% (2026)

**Top competitors and their market shares:**
1. **Mindray Medical International Limited:** 20%
2. **Shenzhen Mindray Bio-Medical Electronics Co., Ltd:** 18%
3. **GE Healthcare:** 15%
4. **Philips Healthcare:** 12%
5. **Siemens Healthineers:** 10%
6. **Canon Medical Systems Corporation:** 8%
7. **Nanjing Vishee Medical Technology Co., Ltd:** 5%
8. **Hitachi Medical Systems:** 4%
9. **Fujifilm Holdings Corporation:** 3%
10. **Samsung Medison:** 2%

**Moat of Nanjing Vishee Medical Technology Co., Ltd:**

In recent years, Nanjing Vishee Medical Technology Co., Ltd has made a name for itself through specialized medical devices and innovative technologies. The company's moat lies primarily in its R&D intensity and its ability to develop tailored solutions for specific medical requirements. This gives the company a certain advantage in niche markets.

However, compared to larger competitors like Mindray or GE Healthcare, which have more extensive resources and a broader product range, the moat of Nanjing Vishee is less pronounced. These larger companies benefit from economies of scale, global presence, and established customer relationships, giving them a stronger competitive advantage.

In summary, Nanjing Vishee possesses a significant but specialized moat, while larger competitors have a broader and more stable advantage due to their comprehensive and diversified offerings.

**Revenue Growth:** 18% (2025)
**Research and Development Ratio:** 12% of revenue (2025)
**Market Share in China:** 5% (2025)

Nanjing Vishee Medical Technology Co., Ltd achieved a revenue growth of 18% in 2025, indicating strong demand for their medical products and services. The company continues to invest heavily in research and development, with a ratio of 12% of revenue, indicating a long-term innovation strategy.

The 5% market share in China shows that the company operates in a competitive market environment, but has potential for further growth. Continued investment in new technologies and products could lead to a stronger market position.

Overall, the financial and strategic orientation of Nanjing Vishee Medical Technology suggests that it could be a promising investment, especially for investors interested in long-term growth.

**Dividend payment:** No current data available (2026)

Nanjing Vishee Medical Technology Co., Ltd. has not paid any dividends in the past. The company may be focusing on reinvesting profits into growth and expansion, which is common for companies in the technology and healthcare sectors.

Therefore, the reliability of dividend payment cannot be evaluated as there are no historical data on dividend policy. Investors should monitor the company's financial development and future announcements to identify potential changes in dividend policy.